Skip to content
Open access

Real-world characteristics and invasive disease-free survival of resected patients with HR-positive/HER2-negative early breast cancer: evidence from German population-based cancer registries

Sep 2026 · ESMO real world data and digital oncology · Vol 13 · 0 citations · 33 references
Medicine

Abstract

Background Hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) tumors are the most prevalent subtypes of early breast cancer (eBC). Despite the generally favorable prognosis, a relevant proportion experiences invasive disease events following surgery. We aimed to describe characteristics, treatment modalities, and survival outcomes of surgically treated patients with HR-positive/HER2-negative eBC in Germany. Materials and methods This study used data from eight population-based clinical cancer registries in Germany. Patients diagnosed between 2017 and 2021 with HR-positive/HER2-negative eBC who underwent surgery within 4 months of diagnosis were included. Patient and tumor characteristics and treatment received before recurrence were described. Kaplan–Meier statistics and multivariable Cox regression were used to assess invasive disease-free survival (iDFS). Results A total of 43 214 patients with a median follow-up time of 47 months were included. Among these, 5635 experienced an iDFS event, of which 38.0% were recurrences as the first observed event. Recurrence more often occurred among men, premenopausal women, and patients with larger tumors, greater nodal involvement, and higher tumor grade. The 5-year iDFS was 82.9% (95% confidence interval 82.4-83.3). In multivariable analysis, higher age, tumor size, nodal involvement, histologic grade, and mastectomy compared with breast-conserving surgery were associated with a lower iDFS. Conclusions These real-world data emphasize that 83% of patients with HR-positive/HER2-negative eBC do not experience recurrence, second primary malignancy, and death within 5 years. The prognostic relevance of established tumor-related factors for iDFS was confirmed in a large unselected patient population in the German routine care setting.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.